NOVALIQ ANNOUNCES POSITIVE TOPLINE RESULTS FOR ITS SEECASE PHASE 2 RIAL OF NOV03 FOR THE TREATMENT OF PATIENTS WITH DRY EYE DISEASE
Novaliq, a specialty pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology for ophthalmology, today announces positive topline results for its EECASE phase 2 clinical trial of NOV03 for the treatment of dry eye disease (DED) in ore than 300 patients.